Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Intergenerational epigenetic inheritance of cancer susceptibility in mammals.

Lesch BJ, Tothova Z, Morgan EA, Liao Z, Bronson RT, Ebert BL, Page DC.

Elife. 2019 Apr 9;8. pii: e39380. doi: 10.7554/eLife.39380.

2.

Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia.

Tothova Z, Krill-Burger JM, Popova KD, Landers CC, Sievers QL, Yudovich D, Belizaire R, Aster JC, Morgan EA, Tsherniak A, Ebert BL.

Cell Stem Cell. 2017 Oct 5;21(4):547-555.e8. doi: 10.1016/j.stem.2017.07.015.

3.

Doubling Down on Mutant RAS Can MEK or Break Leukemia.

Tothova Z, Ebert BL.

Cell. 2017 Feb 23;168(5):749-750. doi: 10.1016/j.cell.2017.02.013.

4.

Resting End-Tidal Carbon Dioxide Predicts Respiratory Complications in Patients Undergoing Thoracic Surgical Procedures.

Brat K, Tothova Z, Merta Z, Taskova A, Homolka P, Vasakova M, Skrickova J, Sramek V, Olson LJ, Cundrle I Jr.

Ann Thorac Surg. 2016 Nov;102(5):1725-1730. doi: 10.1016/j.athoracsur.2016.05.070. Epub 2016 Aug 3.

PMID:
27496629
5.

Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML.

Puram RV, Kowalczyk MS, de Boer CG, Schneider RK, Miller PG, McConkey M, Tothova Z, Tejero H, Heckl D, Järås M, Chen MC, Li H, Tamayo A, Cowley GS, Rozenblatt-Rosen O, Al-Shahrour F, Regev A, Ebert BL.

Cell. 2016 Apr 7;165(2):303-16. doi: 10.1016/j.cell.2016.03.015.

6.

Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.

Elf S, Abdelfattah NS, Chen E, Perales-Patón J, Rosen EA, Ko A, Peisker F, Florescu N, Giannini S, Wolach O, Morgan EA, Tothova Z, Losman JA, Schneider RK, Al-Shahrour F, Mullally A.

Cancer Discov. 2016 Apr;6(4):368-81. doi: 10.1158/2159-8290.CD-15-1434. Epub 2016 Mar 7.

7.

Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9.

Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, Smith I, Tothova Z, Wilen C, Orchard R, Virgin HW, Listgarten J, Root DE.

Nat Biotechnol. 2016 Feb;34(2):184-191. doi: 10.1038/nbt.3437. Epub 2016 Jan 18.

8.

[Heterotopic mesenteric ossification].

Bakoš M, Korček J, Rusev P, Kuťka M, Sládeček A, Tóthová Z.

Rozhl Chir. 2015 Jul;94(7):301-5. Czech.

PMID:
26305351
9.

Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation.

Doench JG, Hartenian E, Graham DB, Tothova Z, Hegde M, Smith I, Sullender M, Ebert BL, Xavier RJ, Root DE.

Nat Biotechnol. 2014 Dec;32(12):1262-7. doi: 10.1038/nbt.3026. Epub 2014 Sep 3.

10.

Hemophagocytic Syndrome and Critical Illness: New Insights into Diagnosis and Management.

Tothova Z, Berliner N.

J Intensive Care Med. 2015 Oct;30(7):401-12. doi: 10.1177/0885066613517076. Epub 2014 Jan 8. Review.

11.

Niche-based screening identifies small-molecule inhibitors of leukemia stem cells.

Hartwell KA, Miller PG, Mukherjee S, Kahn AR, Stewart AL, Logan DJ, Negri JM, Duvet M, Järås M, Puram R, Dancik V, Al-Shahrour F, Kindler T, Tothova Z, Chattopadhyay S, Hasaka T, Narayan R, Dai M, Huang C, Shterental S, Chu LP, Haydu JE, Shieh JH, Steensma DP, Munoz B, Bittker JA, Shamji AF, Clemons PA, Tolliday NJ, Carpenter AE, Gilliland DG, Stern AM, Moore MAS, Scadden DT, Schreiber SL, Ebert BL, Golub TR.

Nat Chem Biol. 2013 Dec;9(12):840-848. doi: 10.1038/nchembio.1367. Epub 2013 Oct 27.

12.

New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice.

Tothova Z, Steensma DP, Ebert BL.

Clin Cancer Res. 2013 Apr 1;19(7):1637-43. doi: 10.1158/1078-0432.CCR-12-1251. Epub 2013 Jan 17. Review.

13.

Anaplastic lymphoma kinase-directed therapy in inflammatory myofibroblastic tumors.

Tothova Z, Wagner AJ.

Curr Opin Oncol. 2012 Jul;24(4):409-13. doi: 10.1097/CCO.0b013e328354c155. Review.

PMID:
22664824
14.

AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias.

Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, Ferraro F, Mercier F, Singh H, Brumme KM, Acharya SS, Scholl C, Tothova Z, Attar EC, Fröhling S, DePinho RA, Armstrong SA, Gilliland DG, Scadden DT.

Cell. 2011 Sep 2;146(5):697-708. doi: 10.1016/j.cell.2011.07.032. Erratum in: Cell. 2011 Sep 30;147(1):247. Schöll, Claudia [corrected to Scholl, Claudia].

15.

Crosstalk between NOTCH and AKT signaling during murine megakaryocyte lineage specification.

Cornejo MG, Mabialah V, Sykes SM, Khandan T, Lo Celso C, Lopez CK, Rivera-Muñoz P, Rameau P, Tothova Z, Aster JC, DePinho RA, Scadden DT, Gilliland DG, Mercher T.

Blood. 2011 Aug 4;118(5):1264-73. doi: 10.1182/blood-2011-01-328567. Epub 2011 Jun 7.

16.

mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion.

Lee JY, Nakada D, Yilmaz OH, Tothova Z, Joseph NM, Lim MS, Gilliland DG, Morrison SJ.

Cell Stem Cell. 2010 Nov 5;7(5):593-605. doi: 10.1016/j.stem.2010.09.015.

17.

A radical bailout strategy for cancer stem cells.

Tothova Z, Gilliland DG.

Cell Stem Cell. 2009 Mar 6;4(3):196-7. doi: 10.1016/j.stem.2009.02.008.

18.

FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system.

Tothova Z, Gilliland DG.

Cell Stem Cell. 2007 Aug 16;1(2):140-52. doi: 10.1016/j.stem.2007.07.017. Review.

19.

FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.

Lee BH, Tothova Z, Levine RL, Anderson K, Buza-Vidas N, Cullen DE, McDowell EP, Adelsperger J, Fröhling S, Huntly BJ, Beran M, Jacobsen SE, Gilliland DG.

Cancer Cell. 2007 Oct;12(4):367-80.

20.

[FoxO: stress or eternal life].

Tothova Z, Mercher T.

Med Sci (Paris). 2007 May;23(5):466-7. French. No abstract available.

21.

The retinoblastoma binding protein RBP2 is an H3K4 demethylase.

Klose RJ, Yan Q, Tothova Z, Yamane K, Erdjument-Bromage H, Tempst P, Gilliland DG, Zhang Y, Kaelin WG Jr.

Cell. 2007 Mar 9;128(5):889-900. Epub 2007 Feb 22.

22.

FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress.

Tothova Z, Kollipara R, Huntly BJ, Lee BH, Castrillon DH, Cullen DE, McDowell EP, Lazo-Kallanian S, Williams IR, Sears C, Armstrong SA, Passegué E, DePinho RA, Gilliland DG.

Cell. 2007 Jan 26;128(2):325-39.

23.

FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis.

Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, Miao L, Tothova Z, Horner JW, Carrasco DR, Jiang S, Gilliland DG, Chin L, Wong WH, Castrillon DH, DePinho RA.

Cell. 2007 Jan 26;128(2):309-23.

24.

The telomerase reverse transcriptase regulates chromatin state and DNA damage responses.

Masutomi K, Possemato R, Wong JM, Currier JL, Tothova Z, Manola JB, Ganesan S, Lansdorp PM, Collins K, Hahn WC.

Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8222-7. Epub 2005 May 31.

25.

[The cases of penetrating eye injuries with large intraocular foreign body].

Jurecka T, Kanovskỳ R, Synek S, Tóthová Z.

Cesk Slov Oftalmol. 2005 Jan;61(1):30-7. Czech.

PMID:
15782856
26.

NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a.

Gu TL, Tothova Z, Scheijen B, Griffin JD, Gilliland DG, Sternberg DW.

Blood. 2004 Jun 15;103(12):4622-9. Epub 2004 Feb 12.

PMID:
14962911

Supplemental Content

Loading ...
Support Center